C12N 2770/20011
Coronaviridae
C12N2770/20011 (Coronaviridae) appears on 781 US grants and 2,154 published applications in this corpus.
Search patents in C12N- Granted patents
- 781
- Published applications
- 2,154
- Assignees
- 1,098
- Inventors
- 5,479
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 5 | 0 |
| 1992 | 3 | 0 |
| 1993 | 5 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 8 | 0 |
| 1999 | 10 | 0 |
| 2000 | 17 | 0 |
| 2001 | 9 | 2 |
| 2002 | 10 | 10 |
| 2003 | 7 | 13 |
| 2004 | 0 | 15 |
| 2005 | 3 | 30 |
| 2006 | 10 | 46 |
| 2007 | 8 | 29 |
| 2008 | 19 | 20 |
| 2009 | 17 | 30 |
| 2010 | 14 | 19 |
| 2011 | 12 | 20 |
| 2012 | 5 | 15 |
| 2013 | 13 | 10 |
| 2014 | 12 | 15 |
| 2015 | 7 | 21 |
| 2016 | 15 | 26 |
| 2017 | 19 | 29 |
| 2018 | 23 | 29 |
| 2019 | 23 | 31 |
| 2020 | 26 | 41 |
| 2021 | 53 | 132 |
| 2022 | 68 | 208 |
| 2023 | 66 | 452 |
| 2024 | 85 | 438 |
| 2025 | 96 | 320 |
| 2026 | 71 | 153 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/20034Use of virus or viral component as vaccineIndexing code551
- C12N 2770/20022New viral proteins or individual genes, new structural or functional aspects ofIndexing code386
- C12N 2770/20071Demonstrated in vivo effectIndexing code90
- C12N 2770/20021Viruses as suchIndexing code63
- C12N 2770/20061Methods of inactivation or attenuationIndexing code56
- C12N 2770/20051Methods of production or purification of viral materialIndexing code37
- C12N 2770/20041Use of virus, viral particle or viral elements as a vectorIndexing code23
- C12N 2770/20023Virus like particles [vlp]Indexing code22
All 12 subgroupsShow fewer
Recent patents
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- High-potency SARS coronavirus 2 antigen and vaccine composition comprising same29 Sep 2026US 12,747,268 B2Korea Research Institute of Chemical Technology
- Variant strain-based coronavirus vaccines22 Sep 2026US 12,741,019 B2ModernaTX, Inc.
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Replicon dna, cloning vector, screening kit, screening method, anti-nobecov-irus agent, beta-coronavirus proliferation inhibitor, pan beta-coronavirus inhibitor, virus proliferation inhibitor, hepatitis c virus proliferation inhibitor, and method for screening therapeutic agent for viral infectious disease8 Oct 2026US 2026/0308206 A1Kagoshima University
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Coronavirus s2 immunogens1 Oct 2026US 2026/0295034 A1The Scripps Research Institute
Most cited
By later US patents
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Method of inducing an immune response with a live Venezuelan Equine Encephalitis virus expressing a heterologous immunogen123US 5,643,576 AThe University of North Carolina at Chapel Hill · 1997
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen109US 9,669,089 B2CureVac AG · 2017